BGI Expands its Shenzhen and Hong Kong Branches with Addition of 12 Illumina Genome Analyzers
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Illumina, Inc. has announced that BGI purchased 12 additional Genome Analyzers, expanding their installed base of Illumina’s next-generation sequencing platforms to 29 units. Of the new units, four will be installed at BGI, Shenzhen and eight will be installed at BGI, Hong Kong.
This added capacity will help researchers at BGI expedite efforts around key programs such as the 1000 Genomes Project, the Chinese Cancer Genome project, the Tree of Life project, and other initiatives that accelerate BGI’s work in agriculture, human health, and biofuels.
“Purchasing 12 Genome Analyzers from Illumina is the first step in a multi-phase scale-up effort we plan to carry out in the near future. And with the opening of our new research facility in Hong Kong we wanted to arm our team of scientists with what we believe is the best in class sequencing technology,” said Xiuqing Zhang, Ph.D., Director of Sequencing Division at BGI.
This added capacity will help researchers at BGI expedite efforts around key programs such as the 1000 Genomes Project, the Chinese Cancer Genome project, the Tree of Life project, and other initiatives that accelerate BGI’s work in agriculture, human health, and biofuels.
“Purchasing 12 Genome Analyzers from Illumina is the first step in a multi-phase scale-up effort we plan to carry out in the near future. And with the opening of our new research facility in Hong Kong we wanted to arm our team of scientists with what we believe is the best in class sequencing technology,” said Xiuqing Zhang, Ph.D., Director of Sequencing Division at BGI.
